Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Accumulated Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Accumulated Expenses for 9 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a N/A change, with the full-year FY2025 number at $9.7 million, changed N/A from a year prior.
  • Accumulated Expenses was $9.7 million for Q4 2025 at Soleno Therapeutics, up from $7.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.7 million in Q4 2025 to a low of $409000.0 in Q2 2025.